Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT07250477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07250477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Lead sponsor
University of California, Davis
Phase
Phase 2
Overall status
Recruiting
Start date
January 30, 2026
Completion date
December 31, 2036
Enrollment
56 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, non-small cell lung cancer metastatic, non-small cell lung cancer stage iiic, non-small cell lung cancer stage iv, non-small cell lung cancer unresectable